MedTrace Logo

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

NCT03493165 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-05-28

No results posted yet for this study

Summary

Single patient treatment with everolimus.

Conditions

  • Uterine Sarcoma

Interventions

DRUG

Everolimus

mTOR inhibitor

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03493165 on ClinicalTrials.gov